Vaccine for men with high-risk prostate cancer after surgery
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a personalized vaccine (FK-PC101) given after prostate removal surgery for men with high-risk prostate cancer. It aims to see if the vaccine can help prevent the cancer from coming back without the need for additional hormone therapy or radiation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have high-risk or very high-risk prostate cancer as defined by national guidelines.
- At least 3 biopsy cores had 50% or more cancer cells, and your PSA is above 4.
- You are scheduled to have your prostate removed within 3 to 14 days of joining.
- You have not had and will not have radiation, hormone therapy, or other cancer treatments before surgery.
- After surgery, your cancer must have spread outside the prostate, have a high Gleason score, and you must have undetectable PSA at 2 months.
- You are generally healthy with good kidney, liver, and blood counts, and have no other active cancers or serious medical conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental vaccine (2141-V11) combined with standard hormone therapy and an anti-androgen drug before prostate removal surgery. It aims to see if the combination can help the immune system fight the cancer more effectively.
This study tests an experimental vaccine that may help your immune system fight prostate cancer cells. If you have low- or intermediate-risk prostate cancer and are under active surveillance, this vaccine might slow or prevent the cancer from growing.
This trial tests a combination of a personalized peptide vaccine and an antibody therapy for men with prostate cancer that has returned after initial treatment. The goal is to see if this approach can control the cancer without needing stronger hormone therapy.
This trial tests a combination of hormone therapy, a targeted pill (Darolutamide), and an immunotherapy drug (Pembrolizumab) before and after surgery for men with high-risk prostate cancer that has specific genetic features. The goal is to see if this approach helps prevent the cancer from coming back.
This trial tests whether giving hormone therapy (androgen deprivation therapy) before surgery can improve outcomes for men with high-risk prostate cancer. You will receive a special PSMA PET/CT scan to see how the cancer responds.
This trial tests different drugs before prostate surgery based on a person's genetic profile. It aims to find better treatments for high-risk prostate cancer that hasn't spread yet.
Hear when a new Prostate Cancer (Adenocarcinoma) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.